aTyr Pharma Inc.

NASDAQ: LIFE · Real-Time Price · USD
1.90
0.05 (2.70%)
At close: Jun 04, 2024, 10:00 PM

aTyr Pharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
-4.67M -4.43M 4.55M 4.9M 4.9M 4.67M 10.74M 10.39M 10.39M 10.39M n/a n/a n/a n/a 2.05M 2.2M 2.39M
Cost of Revenue
2.17M 2.94M 1.18M 2.17M 2.76M 2.74M 3.03M 2.45M 2.15M 1.4M 700K 286K n/a n/a n/a n/a n/a
Gross Profit
-2.73M -2.67M 3.97M 3.33M 2.75M 1.93M 7.71M 7.93M 8.23M 8.99M -700K -286K n/a n/a 2.05M 2.2M 2.39M
Operating Income
-73.94M -74.8M -68.05M -62.52M -58.77M -54.92M -46.91M -47.79M -46.81M -46.4M -47.09M -41.33M -39.19M -34.02M -30.32M -29.1M -24.97M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-70.88M -71.49M -63.81M -57.89M -53.93M -50.4M -43.16M -45.06M -45.14M -45.34M -46.38M -40.8M -38.78M -33.78M -30.15M -29.08M -25.14M
Net Income
-70.88M -71.49M -63.82M -57.9M -53.93M -49.55M -41.89M -43.55M -43.46M -44.28M -45.74M -40.41M -38.55M -33.77M -30.14M -29.07M -25.13M
Selling & General & Admin
16.23M 15.78M 13.39M 12.7M 13.08M 12.98M 13.2M 14.18M 13.91M 13.98M 13.24M 12.21M 11.55M 10.75M 10.36M 9.81M 9.17M
Research & Development
58.53M 60.08M 54.9M 50.41M 46.28M 42.29M 44.45M 44M 43.29M 42.81M 33.85M 29.12M 27.64M 23.26M 22.01M 21.48M 18.19M
Other Expenses
n/a 1.15M 2.35M 3.62M 4.84M 4.52M 3.75M 2.73M 1.67M 837K 489K 301K 191K 238K 164K 105K 52K
Operating Expenses
74.76M 75.86M 68.29M 63.11M 59.36M 55.27M 57.65M 58.17M 57.2M 56.79M 47.09M 41.33M 39.19M 34.02M 32.37M 31.3M 27.36M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
1.18M 1.18M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
25.7M 42.57M 32.83M 45.8M 59.36M 55.27M 57.65M 58.17M 57.2M 56.79M 47.09M 41.33M 39.19M 34.02M 32.37M 31.3M 27.36M
Income Tax Expense
n/a n/a -1K -1K -5K -841K -1.27M -1.52M -1.68M -1.07M -630K -713K -550K -626K -630K -600K -600K
Shares Outstanding (Basic)
75.8M 75.8M 75.8M 72.28M 66.08M 59.26M 57.89M 55.14M 41.9M 29.12M 28.66M 28.06M 27.82M 27.78M 18.16M 16.13M 14.1M
Shares Outstanding (Diluted)
75.8M 75.8M 75.8M 72.28M 66.08M 59.26M 57.89M 55.14M 41.9M 29.12M 28.66M 28.06M 27.82M 27.79M 18.16M 16.13M 14.1M
EPS (Basic)
-0.96 -0.99 -0.94 -0.91 -0.9 -0.94 -0.93 -1.18 -1.4 -1.56 -1.63 -1.6 -1.8 -1.88 -2.04 -2.3 -2.35
EPS (Diluted)
-0.96 -0.99 -0.94 -0.91 -0.9 -0.94 -0.93 -1.18 -1.4 -1.56 -1.63 -1.6 -1.8 -1.88 -2.04 -2.3 -2.35
EBITDA
-70.88M -71.87M -64.98M -60.34M -57.01M -53.17M -45.57M -46.45M -45.77M -45.82M -46.51M -40.75M -38.53M -33.66M -29.96M -28.74M -24.61M
EBIT
-70.88M -72.64M -64.13M -46.87M -44.12M -40.27M -34.57M -48.23M -47.25M -46.84M -38.62M -24.96M -22.82M -10.45M -10.45M -10.45M -6.32M
Depreciation & Amortization
n/a 770K 1.18M 2.17M 2.76M 2.74M 3.03M 2.45M 2.15M 1.7M 1.32M 1.23M 1.3M 1.3M 1.23M 1.2M 1.21M